Effectiveness of DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the United States
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 09 Apr 2019 Planned primary completion date changed from 30 Sep 2018 to 30 Sep 2020.
- 09 Apr 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 23 May 2018 New trial record